High prevalence of *Escherichia coli* sequence type 131 among antimicrobial-resistant *E. coli* isolates from geriatric patients

Pak-Leung Ho,1 Yuki Pui-Shan Chu,2 Wai-U Lo,1 Kin-Hung Chow,1 Pierra Y. Law,1 Cindy Wing-Sze Tse,3 Tak-Keung Ng,4 Vincent Chi-Chung Cheng1 and Tak-Lun Que2

1Department of Microbiology and Carol Yu Centre for Infection, University of Hong Kong, Hong Kong SAR, PR China
2Department of Clinical Pathology, Tuen Mun Hospital, Hong Kong SAR, PR China
3Department of Clinical Pathology, Kwong Wah Hospital, Hong Kong SAR, PR China
4Department of Clinical Pathology, Princess Margaret Hospital, Hong Kong SAR, PR China

Previous work on the subclones within *Escherichia coli* ST131 predominantly involved isolates from Western countries. This study assessed the prevalence and antimicrobial resistance attributed to this clonal group. A total of 340 consecutive, non-duplicated urinary *E. coli* isolates originating from four clinical laboratories in Hong Kong in 2013 were tested. ST131 prevalence among the total isolates was 18.5 % (63/340) and was higher among inpatient isolates (23.0 %) than outpatient isolates (11.8 %, \( P < 0.001 \)), and higher among isolates from patients aged \( \geq 65 \) years than from patients aged 18–50 years and 51–64 years (25.4 vs 3.4 and 4.0 %, respectively, \( P < 0.001 \)). Of the 63 ST131 isolates, 43 (68.3 %) isolates belonged to the *H*30 subclone, whereas the remaining isolates belonged to *H*41 (\( n = 17 \)), *H*54 (\( n = 2 \)) and *H*22 (\( n = 1 \)). All *H*30 isolates were ciprofloxacin-resistant, of which 18.6 % (8/43) belonged to the *H*30-Rx subclone. Twenty-six (41.3 %) ST131 isolates were ESBL-producers, of which 19 had *bla*\(_{\text{CTX-M-14}}\) (12 non-*H*30-Rx, two *H*30-Rx and five *H*41), six had *bla*\(_{\text{CTX-M-15}}\) (five non-*H*30-Rx and one *H*30-Rx) and one was *bla*\(_{\text{CTX-M}}\)-negative (*H*30). In conclusion, ST131 accounts for a large share of the antimicrobial-resistant *E. coli* isolates from geriatric patients. Unlike previous reports, ESBL-producing ST131 strains mainly belonged to non-*H*30-Rx rather than the *H*30-Rx subclone, with *bla*\(_{\text{CTX-M-14}}\) as the dominant enzyme type.

INTRODUCTION

The incidence of infections due to antimicrobial-resistant *Escherichia coli* is increasing worldwide (Barber et al., 2013). Resistance rates for cotrimoxazole, fluoroquinolones and third generation cephalosporins, which are often used for empirical therapy, are now above the 15–20 % threshold recommended for choosing first-line antimicrobial agents for empirical treatment in Hong Kong (Ho et al., 2007b; 2010). Discordant therapy may cause treatment failure, persistence and recurrence of infection, leading to more patient morbidity and mortality (Barber et al., 2013; Shin et al., 2012). Emerging resistance in *E. coli* involves acquisition of resistance determinants by susceptible strains and the expansion of pre-existing resistant clones (Naseer & Sundsfjord, 2011). ST131 is a highly successful *E. coli* clone which has received considerable attention due to its wide geographical distribution, ability to cause a wide range of extra-intestinal infections and association with CTX-M \( \beta \)-lactamases and multidrug resistance (Nicolas-Chanoine et al., 2014).

ST131 can be divided into different subclones by other typing methods, of which sequencing the type 1 fimbrial adhesin gene *fimH* is one widely used approach (Weissman et al., 2012). *H*30, designated according to the *fimH30* variant, is currently the most prevalent subclone of ST131 (Nicolas-Chanoine et al., 2014). Two studies involving whole genome sequencing of ST131 isolates collected from multiple countries came to the same conclusion that fluoroquinolone resistance within ST131 was confined almost entirely to the *H*30 subclone and that CTX-M-15 producers clustered within a nested subclone, designated *H*30-Rx (Petty et al., 2014; Price et al., 2013). Reported prevalence of *H*30 and *H*30-Rx among ST131 isolates ranged from 66.7 to 95.8 %
Methods

Study design. A total of 340 non-duplicated urinary E. coli isolates were studied. The isolates were consecutive single-patient E. coli isolates from four clinical microbiology laboratories in Hong Kong over a two week period, from May to June 2013. The laboratories together served about a quarter of the Hong Kong populations in different geographical districts. The inclusion criteria were: (1) patient age 18 years or above, (2) mid-stream urine specimen and (3) significant growth at ≥10^5 c.f.u. ml^-1. Patient identities was kept anonymous. The following information was provided by the submitting laboratories: sex, age, date of collection and patient location (outpatient or inpatient). One isolate per patient was included.

Microbiological methods. The VITEK GNI system (bioMérieux Vitek) was used for bacterial identification. Antibiotic susceptibilities were tested by the disk diffusion method using Mueller–Hinton agar (Oxoid) and interpreted according to the Clinical and Laboratory Standards Institute (CLSI, 2014). All antibiotic discs were obtained commercially (BBL; Becton Dickinson). The double disc synergy test was used for detection of extended-spectrum β-lactamases (ESBL) (Ho et al., 2010). The susceptibility testing of all isolates was performed in a central laboratory at the University of Hong Kong. On each day of testing, standard strains (ATCC 25922 and 35218) were included as quality controls. For each isolate, the resistance score was the number of antimicrobials (including ampicillin, amoxicillin–clavulanate, cefuroxime, ceftriaxone, ertapenem, nalidixic acid, ciprofloxacin, cotrimoxazole, gentamicin, nitrofurantoin and fosfomycin, which were chosen to represent 11 classes) for which it exhibited resistance (including both intermediate and resistant categories).

Molecular studies. PCR assays were used to assign the E. coli isolates to phylogroups A, B1, B2, C, D, E and F (Clermont et al., 2013). Phylogroup B2 isolates were investigated for ST131 status by PCR assays targeting single nucleotide polymorphisms (SNPs) in mdh and gyrB (Johnson et al., 2009) and the O25b variant and SNPs in pabB (Clermont et al., 2009). A subset of the isolates were further tested by multilocus sequence typing (MLST) for confirmation (Wirth et al., 2006). ST131-associated O serotype, fimH subtype and the H30-Rx subclone were determined by established methods (Banerjee et al., 2013b; Clermont et al., 2013b; Clermont et al., 2007; Weismann et al., 2012). The blacTX-M genes were detected by PCR and sequencing using primers with specificity for the CTX-M subgroups (blacCTX-M16, blacCTX-M18, blacCTX-M35, blacCTX-M45, blacCTX-M6 and blacCTX-M220) (Ho et al., 2007a, 2012). Alleles were assigned by sequencing the full-length of blacCTX-M as previously described (Ho et al., 2012).

Results

Patient demographics

A total of 340 urinary isolates were included in the study: 204 (60.0 %) from inpatients, 156 (40.0 %) from outpatients; 259 (76.2 %) from females and 81 (23.8 %) from males. Each laboratory contributed 82–89 isolates. Overall, 50 (14.7 %) were obtained from patients aged 18–50 years, 58 (17.1 %) from patients aged 51–64 years and 232 (68.2 %) from patients aged ≥65 years. The patients had a mean age of 69.7 ± 17.3 years.

Distribution of phylogroups and ST131 by patient sources

Phylogroup B2 predominated among the isolates, with similar frequencies among isolates from different age groups (62.1–66.0 %) and among inpatients (63.7 %) and outpatients (63.2 %) isolates (Table 1). Allele-specific PCR assays targeting mdh and gyrB identified 63 isolates as ST131 of which 45 isolates were also positive for O25b and pabB. One isolate was pabB-positive and mdh-negative, gyrB-positive. MLST confirmed the isolate as ST131. Another 22 isolates were randomly chosen for MLST and all were confirmed to be ST131. The prevalence of ST131 among all urinary isolates was 18.5 % (63/340) overall, but this varied according to isolate sources (Table 1). The prevalence of ST131 was higher among isolates from patients aged ≥65 years (25.4 %) than the other age groups (3.4–4.0 %), and higher among inpatients (23.0 %) than outpatients (11.8 %). Of the 63 ST131 isolates, 45 (71.4%) were serogroup O25b, 17 (27.0 %) were serogroup O16 and one (1.6 %) was O-nontypable. Forty-three (68.3 %) ST131 isolates belonged to the H30 subclone, whereas the remaining 20 isolates belonged to H41 (n = 17), H54 (n = 2) and H22 (n = 1). All H30 isolates were ciprofloxacin-resistant and 18.6 % (8/43) of H30 isolates belonged to the H30-Rx subclone. In general, serogroup O25b isolates were of H30 subclone (93.3 %, 42/45) and serogroup O16 were of H41 subclone (100 %, 17/17). The frequency of H30 subclone was higher among patients aged ≥65 years and inpatients while those for H41 and other fimH subtypes were similar among the patient subsets. In multivariate analysis, age ≥65 years was the only factor significantly associated with ST131 [odds ratio (OR) 8.9, 95 % confidence interval (CI) 3.1–25.1, P<0.001]. H30 (OR 7.3, 95 % CI 2.2–24.1, P=0.001) and H41 (OR 7.9, 95 % CI 1.04–60.6, P=0.046).
Table 1. Distribution of phylogroups and ST131 among 340 urinary E. coli isolates

<table>
<thead>
<tr>
<th>Categories</th>
<th>No. (column %) by age group</th>
<th>P</th>
<th>No. (column %) by source</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n 18–50 years (n=50)</td>
<td>51–64 years (n=58)</td>
<td>≥65 years (n=232)</td>
<td></td>
</tr>
<tr>
<td>ST131</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H30 subclone</td>
<td>43 1 (2.0)</td>
<td>2 (3.4)</td>
<td>40 (17.2)</td>
<td>0.001</td>
</tr>
<tr>
<td>H41 subclone</td>
<td>17 1 (2.0)</td>
<td>0 (0)</td>
<td>16 (6.9)</td>
<td>0.056</td>
</tr>
<tr>
<td>Others*</td>
<td>3 0 (0)</td>
<td>0 (0)</td>
<td>3 (1.3)</td>
<td>0.494</td>
</tr>
<tr>
<td>Subtotal</td>
<td>63 2 (4.0)</td>
<td>2 (3.4)</td>
<td>59 (25.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>H30-Rx</td>
<td>8 0 (0)</td>
<td>1 (1.7)</td>
<td>7 (3.0)</td>
<td>0.417</td>
</tr>
</tbody>
</table>

*Including H54 (two isolates) and H22 (one isolate).

Distribution of antibiotic resistance by ST131 status

Among ST131 isolates, resistance rates for 8 of the 11 antimicrobials were high, ranging from 33.3 to 87.3 %, while resistance to nitrofurantoin (1.6 %) and fosfomycin (1.6 %) was rare. All isolates including all ST131 subclones were susceptible to ertapenem. ST131 isolates were significantly more likely than non-ST131 isolates to be resistant to ampicillin (87.3 vs 67.9 %, respectively), amoxicillin–clavulanate (33.3 vs 18.8 %), cefuroxime (41.3 vs 20.9 %), nalidixic acid (100 vs 69.0 %), ciprofloxacin (71.4 vs 32.5 %) and gentamicin (38.1 vs 25.6 %), and to be ESBL-producers (41.3 vs 18.8 %). Resistance rates among H30 and H41 isolates were similar except for resistance to ciprofloxacin, which is substantially higher among H30 isolates (100 % for H30 vs 11.8 % for H41, P<0.001). The resistance score was highest for H30 isolates (5.1±2.0), followed by H41 isolates (3.5±1.4) and non-ST131 isolates (3.0±2.4). Within H30 isolates, resistance scores for H30-Rx (4.9±2.7) and non-H30-Rx (5.1±1.8) isolates were similar (P=0.737).

Rates of ESBL production and ciprofloxacin, cotrimoxazole and gentamicin resistance were similar among isolates from different age groups. ST131 accounted for 33.3, 33.3 and 25.3 % of all ESBL-producing, ciprofloxacin-resistant and gentamicin-resistant E. coli populations, respectively. In contrast, prevalence of ST131 among the antimicrobial-sensitive counterparts was significantly lower (P<0.05 for all comparisons), being 14.1 % for ESBL-negative isolates, 8.8 % for ciprofloxacin-sensitive isolates and 15.9 % for gentamicin-sensitive isolates. The prevalence of ST131 among cotrimoxazole-resistant (17.4 %) and -sensitive (19.2 %) isolates was similar. Stratification by age groups revealed that there were variations in the resistant populations attributed to ST131 (Fig. 1). Among the ST131 isolates, 26 (41.3 %) were ESBL-producers. PCR and sequencing showed that 19 had bla<sub>CTX-M-14</sub> (12 non-H30-Rx, two H30-Rx and five H41), six had bla<sub>CTX-M-15</sub> (five non-H30-Rx and one H30-Rx) and one was bla<sub>CTX-M</sub>-negative (H30).

DISCUSSION

We evaluated 340 E. coli urine isolates, collected from four laboratories in 2013, for the ST131 clonal group and its subclones. The prevalence of ST131 among total E. coli isolates (18.5 %) is concordant with other studies in the United States (17–27 %) and Europe (12–22 %) (Nicolas-Chanoine et al., 2014). Our findings showed that the prevalence of ST131 and its H30 subclone was higher among older age, inpatients and antimicrobial-resistant isolates. These findings indicated that expansion of ST131 is an important mechanism of increased antimicrobial resistance in the geriatric population. The reason for the higher prevalence of ST131 among geriatric patients is not clear but could possibly be related to selection from overprescription of broad-spectrum antimicrobials (third generation cephalosporins, fluoroquinolones), institutional acquisition from exposure in old age homes and hospitals and underlying comorbidities (Ho et al., 2014). In previous studies, approximately 25 % of hospitalized patients and elderly residents of long-term care facilities were found to carry ST131 in their faeces (Banerjee & Johnson, 2014), compared with <5 % among healthy young adults (Kudinha et al., 2013; Leflon-Guibout et al., 2008), suggesting institutions may pose risk for ST131 transmission. However, a recent study found that only 2.1 % of 240 residents from 11 nursing homes in Germany had faecal carriage of ST131 (Arvand et al., 2013).

We found that H30 composed 68.3 % of all ST131 isolates, which is lower than the proportions reported for unselected clinical isolates from the United States (87.3 %) and France (86.5 %) (Lafolie et al., 2014). The prevalence of H30-Rx subclone among our H30 isolates was 18.6 %, which is substantially lower than the >70 % among H30 ST131 isolates preselected by specific resistance phenotypes (Banerjee et al., 2013b; Peirano et al., 2014). H30-Rx described previously among isolates from Europe and North America was almost always ESBL-positive and had CTX-M-15 (Peirano et al., 2014; Petty et al., 2014; Price et al., 2013). Here, only three of the eight H30-Rx isolates were ESBL-producers. Unlike previous reports (Peirano et al., 2014; Petty et al., 2014; Price
et al., 2013), ESBL-producing ST131 strains in the present study mainly belonged to non-H30-Rx rather than the H30-Rx subclone. Among all ST131 subclones, CTX-M-14 was the predominant ESBL found. Plasmid IncF family played a major role in the dissemination of CTX-M-15 in Europe and the United States (Nicolás-Chanoine et al., 2014). In Asia, IncF plasmids were found to more often carry CTX-M-14 instead of CTX-M-15 (Ho et al., 2007a; Nicolas-Chanoine et al., 2014). Among ST131 isolates, IncF plasmids carrying CTX-M-14 have been reported from Hong Kong, mainland China and South Korea (Ho et al., 2012; Nicolas-Chanoine et al., 2014). In Japan, CTX-M-14 was detected in 44 and 73% of ESBL-producing ST131-O25b and ST131-O16 isolates, respectively, compared with 18 and 8% for CTX-M-15, respectively (Matsumura et al., 2012).

In summary, this study found that antimicrobial-resistant E. coli from geriatric patients are substantially more likely to be caused by ST131 than are those from younger patients, and that the H30 and H41 subclones possess certain resistance traits different from those reported in other locales.

ACKNOWLEDGEMENTS

This work was supported by grants from the Health and Medical Research Fund (formerly Research Fund for the Control of Infectious Diseases) of the Food and Health Bureau of the Government of the HKSAR and the RGC Collaborative Research Fund Project on Syndromic Surveillance and Modelling for Infectious Diseases. The authors declare no competing interests.

REFERENCES


